CDC Advisers Recommend Adding Gardasil 9 to HPV Vaccine Schedule

By Amy Orciari Herman

Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH

The CDC's Advisory Committee on Immunization Practices has recommended that the nine-valent human papillomavirus vaccine (Gardasil 9) be added to the CDC's HPV vaccine recommendations.

Gardasil 9 was approved in December for females aged 9 to 26 years and males aged 9 to 15. The new ACIP recommendation advocates that the vaccine be administered at ages 11 and 12, although it may be given as early as age 9. The group also advises catch-up vaccination for females aged 13 to 26 and for males aged 13 to 21. (Use in males aged 16 to 21 would be off-label.)

Like the original quadrivalent Gardasil, the nine-valent version is given in a three-dose series.